Leda Mannent
Impact in
- Otorhinolaryngology top 0.1%
- Sinusitis and nasal conditions
- Dermatology top 0.2%
- Dermatology and Skin Diseases
Papers in
-
- Sinusitis and nasal conditions 41
- Dermatology 13
- Dermatology and Skin Diseases 13
- Co-authors
- Nikhil Amin (33 shared papers)Joaquim Mullol (19 shared papers)Claus Bachert (28 shared papers)Tanya M. Laidlaw (8 shared papers)Neil M.H. Graham (13 shared papers)Peter William Hellings (14 shared papers)Asif H. Khan (20 shared papers)Gianluca Pirozzi (10 shared papers)
- Journals
- Journal of Allergy and Clinical Immunology (19 papers)The Journal of Allergy and Clinical Immunology In Practice (10 papers)Allergy (8 papers)British Journal of Dermatology (6 papers)The Laryngoscope (5 papers)
- Partner nations
- United StatesFranceBelgium
In The Last Decade
Leda Mannent
89 papers receiving 6.7k citations
Leda Mannent's Hit Papers
Peers
Comparison fields: 5 of 79
- Otorhinolaryngology 2.9k
- Dermatology 1.2k
- Physiology 1.4k
- Immunology and Allergy 275
- Sensory Systems 117
Countries citing papers authored by Leda Mannent
This map shows the geographic impact of Leda Mannent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leda Mannent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leda Mannent more than expected).
Fields of papers citing papers by Leda Mannent
This network shows the impact of papers produced by Leda Mannent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leda Mannent. The network helps show where Leda Mannent may publish in the future.
Co-authors
The 25 scholars most cited alongside Leda Mannent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials Hit paper breakdown → | 2019 | 1186 |
| 2 | Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis Hit paper breakdown → | 2016 | 663 |
| 3 | Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis Hit paper breakdown → | 2019 | 365 |
| 4 | Conjunctivitis in dupilumab clinical trials Hit paper breakdown → | 2019 | 365 |
| 5 | Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts Hit paper breakdown → | 2023 | 338 |
| 6 | Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis Hit paper breakdown → | 2022 | 333 |
| 7 | Chronic Rhinosinusitis with Nasal Polyps and Asthma Hit paper breakdown → | 2020 | 312 |
| 8 | Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 216 |
| 9 | Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis Hit paper breakdown → | 2022 | 191 |
| 10 | Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials Hit paper breakdown → | 2023 | 162 |
| 11 | 2019 | 160 | |
| 12 | 2019 | 155 | |
| 13 | 2018 | 147 | |
| 14 | Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases Hit paper breakdown → | 2021 | 143 |
| 15 | 2019 | 132 | |
| 16 | Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials Hit paper breakdown → | 2024 | 108 |
| 17 | 2021 | 91 | |
| 18 | 2019 | 89 | |
| 19 | Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 89 |
| 20 | 2021 | 87 |
About Leda Mannent
Leda Mannent is a scholar working on Otorhinolaryngology, Dermatology, Physiology, Rheumatology and Surgery, having authored 89 papers that have together received 6.9k indexed citations. Recurring topics across this work include Sinusitis and nasal conditions (41 papers), Asthma and respiratory diseases (16 papers), Dermatology and Skin Diseases (13 papers), Eosinophilic Esophagitis (10 papers), Urticaria and Related Conditions (5 papers), Food Allergy and Anaphylaxis Research (2 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (1 paper) and Traumatic Brain Injury and Neurovascular Disturbances (1 paper). The work is most often cited by research in Otorhinolaryngology (2.9k citations), Dermatology (1.2k citations), Physiology (1.4k citations), Immunology and Allergy (275 citations) and Sensory Systems (117 citations). Leda Mannent has collaborated with scholars based in United States, France and Belgium. Frequent co-authors include Nikhil Amin, Joaquim Mullol, Claus Bachert, Tanya M. Laidlaw, Neil M.H. Graham, Peter William Hellings, Asif H. Khan, Gianluca Pirozzi, Jennifer D. Hamilton and Katharine M. Woessner. Their work appears in journals such as Journal of Allergy and Clinical Immunology, The Journal of Allergy and Clinical Immunology In Practice, Allergy, British Journal of Dermatology and The Laryngoscope.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.